The abstract identifies that neurons show resistance to autophagy induction, but the mechanistic basis remains incompletely defined. Understanding this resistance is crucial for developing neuron-targeted autophagy therapies for ALS.
Gap type: unexplained_observation
Source paper: Autophagy and ALS: mechanistic insights and therapeutic implications. (2022, Autophagy, PMID:34057020)
Neurons uniquely express the PP2A Bβ1 regulatory subunit forming a phosphatase complex that selectively dephosphorylates and activates ULK1 at Ser757 but not Ser317, creating a dominant-negative ULK1 activation state refractory to most autophagy induction strategies. SKEPTIC critique weakened this by noting PPP2R2B is 'neuron-enriched' not 'neuron-exclusive', and the selective dephosphorylation specificity lacks structural validation. DOMAIN_EXPERT identifies this as high-risk requiring structural data on PP2A-Bβ1:ULK1 interface before clinical investment.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["PPP2R2B PP2A Regulatory B55alpha Subunit"]
B["PP2A Heterotrimeric Complex Catalytic and Scaffold"]
C["Tau Dephosphorylation Ser262/396 Sites"]
D["AKT and MYC Regulation Cell Survival Signaling"]
E["PPP2R2B Methylation LEAVES.1 Long Noncoding RNA"]
F["PPP2R2B Silencing Hyperphosphorylated Tau Accumulation"]
G["PP2A Activators DT-061 or Peptide Activators"]
A --> B
B --> C
B --> D
E -.->|"reduces"| B
F -.->|"causes"| C
G -.->|"restores"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784
Median TPM across 13 brain regions for PPP2R2B, ULK1 complex from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
MECH 4CLIN 0GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
PPP2R2B is neuron-enriched and alternatively splic…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-21 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: Neuronal Resistance to Autophagy Induction in ALS
Hypothesis 1: Impaired TFEB/TFE3 Nuclear Translocation Due to mTORC1 Hyperactivity in Motor Neurons
Mechanism: Motor neurons exhibit constitutive mTORC1 activation that phosphorylates TFEB/TFE3 transcription factors, sequestering them in the cytoplasm and preventing transcription of autophagy-lysosomal genes. This creates a "locked" state where general autophagy inducers cannot overcome mTOR-mediated repression of the CLEAR (Coordinated Lysosomal Expression and Regulation) gene network.
**Target Gene/Pro
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Hypotheses: Neuronal Resistance to Autophagy Induction in ALS
Hypothesis 1: Impaired TFEB/TFE3 Nuclear Translocation Due to mTORC1 Hyperactivity
Weak Links:
The evidence for "attenuated responses" to mTOR inhibitors in neurons conflates upstream TFEB activation with downstream execution. If lysosomal function (Hypothesis 3) is the primary bottleneck, mTORC1 inhibition may successfully induce TFEB nuclear translocation without measurable autophagic flux improvement—a confounding variable that inflates the apparent importance of this mechanism.
Constitu
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Feasibility Assessment: Neuronal Autophagy Resistance Mechanisms in ALS
Executive Summary
Of the five proposed hypotheses, the SKEPTIC's critical evaluation substantially weakens three (H1, H2, H5) through mechanistic confounds and non-uniqueness arguments. Two mechanisms (H3, H4) survive rigorous critique and warrant prioritized investigation, though each faces distinct clinical development obstacles.
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "Compromised Lysosomal Acidification and Trafficking Due to Neuronal V-ATPase Subunit Composition", "description": "Neurons express a distinct V-ATPase subunit isoform profile (ATP6V0C splice variants and ATP6V1G2 enrichment) resulting in slower lysosomal acidification kinetics and defective lysosomal transport along microtubules. This creates a bottleneck where fusion-competent autophanosomes cannot efficiently intersect with properly acidified lysosomes, misinterpreted as 'autophagy resistance'. This hypothesis survived SKEPTIC critique w
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF neuronal expression of PP2A-Bβ1 creates a dominant-negative ULK1 state refractory to mTOR inhibition, THEN siRNA-mediated knockdown of PPP2R2B (≥70% knockdown efficiency) in primary mouse cortical neurons will restore rapamycin-induced ULK1 Ser757 dephosphorylation and increase LC3-II/LC3-I ratio by ≥1.5-fold compared to scramble siRNA controls within 72 hours post-transfection.
pendingconf: 0.40
Expected outcome: PPP2R2B knockdown will restore autophagy sensitivity to mTOR inhibition, with rapamycin increasing LC3-II/LC3-I ratio in neurons to levels comparable to PPP2R2B-silenced fibroblasts
Falsified by: If ULK1 Ser757 phosphorylation remains refractory to rapamycin after PPP2R2B knockdown (phospho-Ser757 signal unchanged within 10%), or if LC3-II/LC3-I ratio fails to increase ≥1.5-fold, the dominant-negative ULK1 state hypothesis is falsified
Method: Primary cortical neuron culture from E18 C57BL/6 mice, transfection with PPP2R2B-targeting siRNA ( Dharmacon SMARTpool) or non-targeting control, 72h knockdown followed by 100nM rapamycin for 2h, immunoblotting for phospho-ULK1 Ser757, phospho-ULK1 Ser317, LC3-II/LC3-I, and PPP2R2B with β-actin loading control
IF the PP2A-Bβ1 holoenzyme selectively dephosphorylates ULK1 at Ser757 while sparing Ser317 (as hypothesized), THEN in vitro phosphatase assays using purified recombinant PP2A-Bβ1 complex incubated with dual-phosphorylated ULK1 substrate should show ≥2-fold greater dephosphorylation at Ser757 versus Ser317 within 30 minutes at 37°C.
pendingconf: 0.35
Expected outcome: PP2A-Bβ1 will dephosphorylate ULK1 Ser757 at least twice as fast as Ser317 in vitro, confirming substrate selectivity
Falsified by: If Ser757 and Ser317 are dephosphorylated at similar rates (ratio <1.5), or if Ser317 is dephosphorylated preferentially over Ser757, the selective specificity claim is falsified and the hypothesis weakened
Method: In vitro phosphatase assay: purify PP2A-A/C scaffolding with Bβ1 regulatory subunit from HEK293 cells, incubate with recombinant dual-phosphorylated ULK1 (1-400 aa) containing pSer317 and pSer757, quantify site-specific dephosphorylation kinetics via phospho-specific ELISA or quantitative western blot at 0, 5, 15, 30 minutes